Research article · 27 Jul 2026
Conference abstractPublished 6 Oct 2015
Formulation of dosage forms containing epigenetic agents
Chicago State University, US
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Conventional cancer treatment protocols are either toxic or of minimal therapeutic value, necessitating investigation of new modalities for efficacious treatment and management of cancers. Among the various novel compounds, Histone Deacetylase Inhibitors (HDACIs) target cancer cells over-expressing deacetylases (HDACs). The inhibition of HDACs changes gene expression without altering the DNA sequence. In the present study, an albumin-based microparticulate drug delivery system containing vorinostat was formulated and evaluated for breast cancer therapy. Drug-loaded microparticles were prepared by a microencapsulation method through spray drying. Prepared microparticles containing the active drug were characterized for their physiochemical properties, including size, surface morphology, Zeta potential and surface properties. Dissolution studies were carried out to examine the release profile of the drug from the delivery system. For in vitro characterization and efficacy studies, breast carcinoma HTB-126 wells were used. Histone deacetylase (HDAC) activity was determined from cancer cells, and the efficacy of the free vorinostat and microparticle formulations was compared. Global histone changes in cells were analyzed using two-dimensional polyacrylamide gel electrophoresis (2D-PAGE). Western blot was also utilized to detect acetylation marks in cells. Uptake studies were carried out in cancer cells to examine the internalization capability of microparticle drug formulations. Data indicated that microparticles were approximately 2-Ã?¼m in size with Zeta potential measurements of about -30 mV. Release studies in cells showed that the drug released from the microparticulate delivery system at an extended rate over a period of over 24 hours. In vitro data in cancer cell line indicated that there was at least 10% more inhibition of cell viability when vorinostat was used with the microparticles. Similar results were observed from clonogenic studies. Additionally, in vitro data suggested that cell death induced by the drug-loaded microparticles was caused by apoptosis. Drug-loaded microparticle formulations were able to be internalized into cancer cells. Microparticles were shown to be a promising targeting strategy for cancer epigenetic therapy by providing an extended-release of the drug in the body. Future studies in animals could provide a proof of concept for the role of HDACIs in the therapeutic treatment of cancers.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Clinical Pharmacology & Biopharmaceutics.
Article · 20 Jul 2026
Population Pharmacology: Precision Dosing for Diverse Patients
Article · 17 Jul 2026
Therapeutic Drug Monitoring: Optimizing Therapy, Minimizing Toxicity
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Pharmacology & Biopharmaceutics
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Duc P Do”
